Results 21 to 30 of about 51,884 (210)

Targeting mGlu5 metabotropic glutamate receptors in the treatment of cognitive dysfunction in a mouse model of phenylketonuria [PDF]

open access: yes, 2018
We studied group-I metabotropic glutamate (mGlu) receptors in Pah(enu2) (ENU2) mice, which mimic the genetics and neurobiology of human phenylketonuria (PKU), a metabolic disorder characterized, if untreated, by autism, and intellectual disability (ID ...
Battaglia, Giuseppe   +12 more
core   +2 more sources

Optogenetics-induced activation of glutamate receptors improves memory function in mice with Alzheimer’s disease

open access: yesNeural Regeneration Research, 2019
Optogenetics is a combination of optics and genetics technology that can be used to activate or inhibit specific cells in tissues. It has been used to treat Parkinson’s disease, epilepsy and neurological diseases, but rarely Alzheimer’s disease.
Ke-Wei Wang   +4 more
doaj   +1 more source

Sequences within the C terminus of the metabotropic glutamate receptor 5 (mGluR5) are responsible for inner nuclear membrane localization [PDF]

open access: yes, 2017
Traditionally, G-protein-coupled receptors (GPCR) are thought to be located on the cell surface where they transmit extracellular signals to the cytoplasm.
Harmon, Steven K.   +4 more
core   +2 more sources

Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson\'s Disease

open access: yesBasic and Clinical Neuroscience, 2021
Introduction: Parkinsonchr('39')s disease (PD) presentations comprise frequent movement disorders in the elderly with various symptoms consisting of motor and non-motor complications.
Jamileh Ghalami   +4 more
doaj  

Incentive learning underlying cocaine relapse requires mGluR5 receptors located on dopamine D1 receptor-expressing neurons [PDF]

open access: yes, 2010
Understanding the psychobiological basis of relapse remains a challenge in developing therapies for drug addiction. Relapse in cocaine addiction often occurs following exposure to environmental stimuli previously associated with drug taking.
Bilbao, Ainhoa   +11 more
core   +2 more sources

Bioactive Benzofuran Derivatives from Cortex Mori Radicis, and Their Neuroprotective and Analgesic Activities Mediated by mGluR1

open access: yesMolecules, 2017
Four new benzofuran-type stilbene glycosides and 14 known compounds including 8 benzofuran-type stilbenes and 6 flavonoids were isolated from the traditional Chinese medicine, Cortex Mori Radicis.
Ya-Nan Wang   +13 more
doaj   +1 more source

Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies. [PDF]

open access: yes, 2014
BackgroundIn dementia with Lewy bodies (DLB) abnormal interactions between α-synuclein (α-syn) and beta amyloid (Aβ) result in selective degeneration of neurons in the neocortex, limbic system and striatum.
Cartier, Anna   +9 more
core   +3 more sources

Fragile X mental retardation protein (FMRP) and metabotropic glutamate receptor subtype 5 (mGlu5) control stress granule formation in astrocytes

open access: yesNeurobiology of Disease, 2021
Fragile X syndrome (FXS) is a common form of intellectual disability and autism caused by the lack of Fragile X Mental Retardation Protein (FMRP), an RNA-binding protein involved in RNA transport and protein synthesis.
B. Di Marco   +8 more
doaj   +1 more source

Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease

open access: yesParkinson's Disease, 2010
Clinical trials have demonstrated positive proof of efficacy of dual metabotropic glutamate receptor 2/3 (mGluR2/3) agonists in both anxiety and schizophrenia.
Hugh Chan   +6 more
doaj   +1 more source

mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism. [PDF]

open access: yesPLoS ONE, 2011
Autism spectrum disorders (ASD) are highly disabling developmental disorders with a population prevalence of 1-3%. Despite a strong genetic etiology, there are no current therapeutic options that target the core symptoms of ASD.
Mili V Mehta   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy